Combination Therapy With Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Ustekinumab in Patients With Refractory Crohn's Disease

被引：14

作者：

Tanida, Satoshi ^{[1
]}

Mizoshita, Tsutomu ^{[1
]}

Ozeki, Keiji ^{[1
]}

Katano, Takahito ^{[1
]}

Tanaka, Mamoru ^{[1
]}

Nishie, Hirotada ^{[1
]}

Shimura, Takaya ^{[1
]}

Okamoto, Yasuyuki ^{[1
]}

Kubota, Eiji ^{[1
]}

Kataoka, Hiromi ^{[1
]}

Joh, Takashi ^{[1
]}

机构：

[1] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Aichi, Japan

来源：

THERAPEUTIC APHERESIS AND DIALYSIS | 2018年 / 22卷 / 03期

基金：

日本学术振兴会;

关键词：

Clinical remission; Intensive; Adsorptive; Granulocyte and monocyte apheresis; Refractory Crohn's disease; Simple endoscopic score; Ustekinumab; INFLAMMATORY-BOWEL-DISEASE; PROSPECTIVE RANDOMIZED MULTICENTER; MAINTENANCE THERAPY; INDUCTION; METAANALYSIS; EFFICACY; COLITIS; TRIAL; TNF;

D O I：

10.1111/1744-9987.12697

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ustekinumab is applied to induce clinical remission in patients with Crohn's disease. Granulocyte and monocyte absorptive apheresis depletes activated myeloid lineage leukocytes and has been applied for active Crohn's disease. This study retrospectively examined the efficacy and safety of combining intensive granulocyte and monocyte absorptive apheresis and ustekinumab for remission induction therapy in refractory Crohn's disease. Between June and September 2017, three consecutive cases (two females) with refractory Crohn's disease were treated with intensive granulocyte and monocyte absorptive apheresis plus ustekinumab. Crohn's disease activity index, and simple endoscopic score for Crohn's disease at baseline and 10 weeks were applied as treatment efficacy outcomes. In all three cases, at week 10, clinical remission was achieved, while simple endoscopic score for Crohn's disease reflected no improvement. Thus, combination therapy with intensive granulocyte and monocyte absorptive apheresis plus ustekinumab appeared to represent a safe and effective intervention for inducing clinical remission.

引用

页码：295 / 300

页数：6

共 23 条

[1] Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD [J].

Daperno, M ;

D'Haens, G ;

Van Assche, G ;

Baert, F ;

Bulois, P ;

Maunoury, V ;

Sostegni, R ;

Rocca, R ;

Pera, A ;

Gevers, A ;

Mary, JY ;

Colombel, JF ;

Rutgeerts, P .

GASTROINTESTINAL ENDOSCOPY, 2004, 60 (04) :505-512

[2] Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease [J].

Deepak, Parakkal ;

Sandborn, William J. .

GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2017, 46 (03) :603-+

[3] Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy [J].

Deepak, Parakkal ;

Loftus, Edward V., Jr. .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 :3685-3698

[4] A genome-wide association study identifies IL23R as an inflammatory bowel disease gene [J].

Duerr, Richard H. ;

Taylor, Kent D. ;

Brant, Steven R. ;

Rioux, John D. ;

Silverberg, Mark S. ;

Daly, Mark J. ;

Steinhart, A. Hillary ;

Abraham, Clara ;

Regueiro, Miguel ;

Griffiths, Anne ;

Dassopoulos, Themistocles ;

Bitton, Alain ;

Yang, Huiying ;

Targan, Stephan ;

Datta, Lisa Wu ;

Kistner, Emily O. ;

Schumm, L. Philip ;

Lee, Annette T. ;

Gregersen, Peter K. ;

Barmada, M. Michael ;

Rotter, Jerome I. ;

Nicolae, Dan L. ;

Cho, Judy H. .

SCIENCE, 2006, 314 (5804) :1461-1463

[5] Role of Sensory Neurons in Colitis: Increasing Evidence for a Neuroimmune Link in the Gut [J].

Engel, Matthias A. ;

Becker, Christoph ;

Reeh, Peter W. ;

Neurath, Markus F. .

INFLAMMATORY BOWEL DISEASES, 2011, 17 (04) :1030-1033

[6] Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease [J].

Feagan, B. G. ;

Sandborn, W. J. ;

Gasink, C. ;

Jacobstein, D. ;

Lang, Y. ;

Friedman, J. R. ;

Blank, M. A. ;

Johanns, J. ;

Gao, L. -L. ;

Miao, Y. ;

Adedokun, O. J. ;

Sands, B. E. ;

Hanauer, S. B. ;

Vermeire, S. ;

Targan, S. ;

Ghosh, S. ;

de Villiers, W. J. ;

Colombel, J. -F. ;

Tulassay, Z. ;

Seidler, U. ;

Salzberg, B. A. ;

Desreumaux, P. ;

Lee, S. D. ;

Loftus, E. V., Jr. ;

Dieleman, L. A. ;

Katz, S. ;

Rutgeerts, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1946-1960

[7] Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naive Japanese patients with early-diagnosed Crohn's disease [J].

Fukuchi, Takumi ;

Nakase, Hiroshi ;

Ubukata, Satoshi ;

Matsuura, Minoru ;

Yoshino, Takuya ;

Toyonaga, Takahiko ;

Shimazu, Keiji ;

Koga, Hideaki ;

Yamashita, Hiroshi ;

Ito, Dai ;

Ashida, Kiyoshi .

BMC GASTROENTEROLOGY, 2014, 14

[8] Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed [J].

Gisbert, J. P. ;

Marin, A. C. ;

McNicholl, A. G. ;

Chaparro, M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (07) :613-623

[9] Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial [J].

Hanauer, SB ;

Sandborn, WJ ;

Rutgeerts, P ;

Fedorak, RN ;

Lukas, M ;

Macintosh, D ;

Panaccione, R ;

Wolf, D ;

Pollack, P .

GASTROENTEROLOGY, 2006, 130 (02) :323-332

[10] Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].

Hanauer, SB ;

Feagan, BG ;

Lichtenstein, GR ;

Mayer, LF ;

Schreiber, S ;

Colombel, JF ;

Rachmilewitz, D ;

Wolf, DC ;

Olson, A ;

Bao, WH ;

Rutgeerts, P .

LANCET, 2002, 359 (9317) :1541-1549

← 1 2 3 →